Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this t...